Recombinant protein vaccine
Source: By The Indian Express
Different pharmaceutical companies have taken different approaches to developing Covid-19 vaccines to stimulate longer-lasting immune system response. Recombinant protein vaccine is another proven approach against the deadly Covid-19 virus.
This technology teaches the body how to develop immunity against the novel coronavirus by using virus' spike proteins.
Used by Novavax in developing Covovax vaccine, these vaccines often require the incorporation of adjuvants to generate a stronger response against the virus. According to sources, the Serum Institute of India (SII) is likely to launch clinical trials of the Novavax vaccine for children in July.
"Novavax results are promising. This vaccine is very safe and highly effective. Clinical trials are being conducted and are in an advanced stage of completion, said Dr VK Paul of the Niti Aayog. SII is likely to introduce the Novavax vaccine in the country by September.
This after the vaccine turned out to be more than 90 per cent effective in clinical trials conducted in the US which involved 29,960 participants. Phase-3 trials conducted in the US, demonstrated 100 percent protection against moderate and severe disease.
NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralising antibodies. It contains purified protein antigen and can neither replicate, nor can it cause Covid-19. The vaccine can be stored at 2 to 8 degrees celsius.
